Leerink Partners Maintains Outperform on Trevi Therapeutics, Raises Price Target to $16
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Faisal Khurshid maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $13 to $16.
Leerink Partners analyst Faisal Khurshid maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $13 to $16.